micro-community-banner
 
  • Saved

3yr
Patient-reported outcomes of migraine treatment with erenumab: results from a national patient survey - PubMed

Patient-reported outcomes of migraine treatment with erenumab: results from a national patient survey - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35006445/

Vast majority of patients experience stable or increasing effect of erenumab. * Erenumab efficacy usually becomes evident during the first month of treatment. * Erenumab is perceived significantly better than...


Conclusion: After treatment discontinuation, a rapid migraine worsening was found, despite the high clinical response during treatment and at retreatment, which might be secondary to an untimely interruption of a potentially disease-modifying pharmacologic intervention. Although clinical improvement was documented after retreatment, given the...

  • Saved

3yr
Erenumab Discontinuation After 12-Month Treatment

Erenumab Discontinuation After 12-Month Treatment

Source : https://cp.neurology.org/content/11/6/e834

Objective To assess migraine outcome after 12-month treatment with erenumab and compare patients who underwent 3-month erenumab discontinuation following the first treatment cycle with those who continued monthly administrations. Methods...


Conclusion: Erenumab is perceived as an effective and safe treatment. Further studies are needed to investigate a post-cessation deterioration of achieved improvement.

  • 3yr
    This is quite an interesting study.
  • 4yr
    Key Points • Source: Neurology Clinical Practice • Conclusions/Relevance: “After treatment discontinuation, a rapid migraine worsening was found, despite the high clinical response during treatment and at retreatment, which might be secondary to an Show More
  • Saved

4yr

TRUDHESA DHE (DIHYDROERGOTAMINE) NASAL SPRAY, AND THE TOP 7 REASONS TO CONSIDER DHE FOR MIGRAINE TREATMENT. - Virtual Headache Specialist

TRUDHESA DHE (DIHYDROERGOTAMINE) NASAL SPRAY, AND THE TOP 7 REASONS TO CONSIDER DHE FOR MIGRAINE TREATMENT. - Virtual Headache Specialist

Source : https://virtualheadachespecialist.com/trudhesa-dhe-dihydroergotamine-nasal-spray-and-the-top-7-reasons-to-consider-dhe-for-migraine-treatment/

Intravenous DHE (dihydroergotamine) has always been considered to be one of the most effective medicines in treating refractory migraine and status migrainosus when other medicines such as triptans won't work....

  • 4yr
    Thanks for your contributions [~Dr--Hamid--ayeshahameed09@ ] and [~Huma--Sheikh--huma927@ ] ! What do others think of these new options?
  • 4yr
    Intravenous DHE (dihydroergotamine) has always been considered to be one of the most effective medicines in treating migraine, refractory migraine and status migrainosus, and cluster headache, when other medicines such Show More

Show More Comments

  • Saved

4yr
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men

Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men

Source : https://www.frontiersin.org/articles/10.3389/fneur.2021.774341/full

Objective: We reported gender-specific data on the efficacy and safety of erenumab, a monoclonal antibody antagonizing the calcitonin gene-related peptide (CGRP) receptor.Methods: Our pooled patient-level analysis of real-world data included...


Conclusion: We found that erenumab is equally safe and effective in men compared with women after 12 weeks.

  • Saved

4yr

The impacts of masks and disinfectants on migraine patients in the COVID-19 pandemic

Source : https://doi.org/10.1016/j.jocn.2022.01.006


We found a worsening of migraines in more than half of patients during the COVID-19 pandemic. We also demonstrated a relationship between migraine worsening and mask type, number of masks, and intensive disinfectant use. Migraine patients should be advised of optimal prevention methods based on individual social and working conditions rather...

Show More Comments